A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer
Latest Information Update: 09 Jan 2024
At a glance
- Drugs CHECKVacc (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 22 Sep 2024.
- 02 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 22 Sep 2024.
- 02 Jan 2024 Status changed from recruiting to active, no longer recruiting.